

Monthly statement of total voting rights and shares forming the company's share capital

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris
 ISIN code / Mnemo: CH0308403085 / GNRO
 Web site: www.geneuro.com

Date	Number of shares outstanding	Total voting rights, gross ⁽¹⁾	Total voting rights, net ⁽²⁾
December 31, 2023	24,999,028	24,999,028	24,834,289
January 31, 2024	24,999,028	24,999,028	24,838,270
February 29, 2024 (3)	29,760,933	29,760,933	29,605,377
March 31, 2024	29,760,933	29,760,933	29,612,599
April 30, 2024	29,760,933	29,760,933	29,611,127
May 31, 2024	29,760,933	29,760,933	29,618,634
June 30, 2024	29,760,933	29,760,933	29,621,394

(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is disclosed in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

(3) Taking into account the capital increase completed on February 7, 2024.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

For more information, visit: www.geneuro.com

Contacts

GeNeuro

Miguel Payró
 CFO
 +41 22 552 48 00
investors@geneuro.com

NewCap (France)

Louis-Victor Delouvrier (investors)
 +33 1 44 71 98 52
 Arthur Rouillé (media)
 +33 1 44 71 94 98
geneuro@newcap.eu